Latest News

New biopsies reveal hidden scalp inflammation in dissecting cellulitis, even in normal-looking skin, hinting at a field effect behind stubborn recurrences.

Quoin reported positive interim phase 2/3 results for QRX003, which met the primary endpoint in patients with Netherton syndrome.

Paul Rose, MD, JD, discusses nonscalp hair transplantation, patient selection, common misconceptions, and the future of hair restoration.

Learn more about the in-depth topics covered in the August 2026 issue of Dermatology Times.

The FDA approval, based on phase 3 VALOR trial data, makes brepocitinib the first targeted therapy specifically indicated for dermatomyositis.

Experts map referral pathways and team-based immunotherapy care for advanced cutaneous squamous cell carcinoma, tackling toxicity and follow-up gaps.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of August.

Verrica Pharmaceuticals has completed enrollment in COVE-2, its first pivotal phase 3 trial of YCANTH for common warts, with topline data expected in the first quarter of 2027.

Experts weigh checkpoint inhibitors for advanced cutaneous squamous cell carcinoma, highlighting real-world safety, immunotherapy referrals, and where cosibelimab may belong.

A secondary analysis of the phase 3 VALOR trial found brepocitinib 30 mg nearly doubled remission-level skin responses and improved itch as early as week 4 compared with placebo.

Shawna Jones, PA-C, shares a road map to aesthetics, emphasizing clinical judgment, anatomy, patient trust, safety, and lifelong learning.

This review of the latest dermatological studies includes insights on multimodal imaging for rosacea evaluation, growth in pediatric AD patients, botulinum toxin for post-acne sequelae, and more.

Rezpegaldesleukin improved EASI, itch, and other outcomes in phase 2b REZOLVE-AD, supporting continued phase 3 development.